Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis
Open Access
- 20 October 2005
- journal article
- practice guideline
- Published by Wiley in European Journal of Neurology
- Vol. 12 (11), 817-827
- https://doi.org/10.1111/j.1468-1331.2005.01386.x
Abstract
Therapy‐induced binding and neutralizing antibodies is a major problem in interferon (IFN)‐β treatment of multiple sclerosis. The objective of this study was to provide guidelines outlining the methods and clinical use of the measurements of binding and neutralizing antibodies. Systematic search of the Medline database for available publications on binding and neutralizing antibodies was undertaken. Appropriate publications were reviewed by one or more of the task force members. Grading of evidence and recommendations was based on consensus by all task force members. Measurements of binding antibodies are recommended for IFN‐β antibody screening before performing a neutralizing antibody (NAB) assay (Level A recommendation). Measurement of NABs should be performed in specialized laboratories with a validated cytopathic effect assay or MxA production assay using serial dilution of the test sera. The NAB titre should be calculated using the Kawade formula (Level A recommendation). Tests for the presence of NABs should be performed in all patients at 12 and 24 months of therapy (Level A recommendation). In patients who remain NAB‐negative during this period measurements of NABs can be discontinued (Level B recommendation). In patient with NABs, measurements should be repeated, and therapy with IFN‐β should be discontinued in patients with high titres of NABs sustained at repeated measurements with 3‐ to 6‐month intervals (Level A recommendation).Keywords
This publication has 60 references indexed in Scilit:
- Comparisons of Visual Properties between Tectal and Thalamic Neurons with Overlapping Receptive Fields in the PigeonBrain, Behavior and Evolution, 2004
- Interspecific Allometry of the Brain and Brain Regions in Parrots (Psittaciformes): Comparisons with Other Birds and PrimatesBrain, Behavior and Evolution, 2004
- Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004*European Journal of Neurology, 2004
- A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFNJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Incidence of Autoantibodies Against Type I and Type II Interferons in a Cohort of Systemic Lupus Erythematosus Patients in SlovakiaJournal of Interferon & Cytokine Research, 2003
- Discordant Effect of IFN-β1a Therapy on Anti-IFN Antibodies and Thyroid Disease Development in Patients with Multiple SclerosisJournal of Interferon & Cytokine Research, 2002
- Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2001
- The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay SystemsJournal of Interferon & Cytokine Research, 2001
- Low frequency of neutralizing antibodies against natural interferon-β during adjuvant therapy for Japanese patients with melanomaJournal of Dermatological Science, 1999
- Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-β1b-treated multiple sclerosis patientsMultiple Sclerosis Journal, 1998